{"links":{"html":"https://www.erudio.com/reports/ko-men-017-nct07007312","json":"https://www.erudio.com/reports/ko-men-017-nct07007312.json","markdown":"https://www.erudio.com/reports/ko-men-017-nct07007312.md","mcp":{"server":"https://mcp.erudio.com/mcp","tool":"get_report_card","arguments":{"slug":"ko-men-017-07007312"}},"request":"https://www.erudio.com/contact?report=ko-men-017-07007312"},"offer":{"cited_commentary_sources":7,"verified_hcp_statements":34,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI. For scientific and insight use inside the organization, not for promotional targeting or outreach. Every report already names and describes its speakers.","available_with":"12-month updates","cap_usd":750,"identity_verified_people":5,"optional":true,"price_per_verified_person_usd":15,"price_usd":75,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_tools":["create_order","get_order","recover_key"],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"ko-men-017-nct07007312"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=ko-men-017-07007312","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/ko-men-017-nct07007312","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-19T01:10:16.551444Z","notify_subscribers":false,"status":"corrected","summary":"taxonomy mapping corrected"},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":1},"aspects":[{"claim_count":1,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS)"},{"claim_count":1,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":1,"title":"Primary endpoint: Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T3","registry_field":"outcomesModule.primaryOutcomes[2]","source_count":0,"title":"Primary endpoint: Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS)"},{"claim_count":1,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.primaryOutcomes[3]","source_count":1,"title":"Primary endpoint: Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients"},{"claim_count":9,"coverage":"discussed","id":"T5","registry_field":"outcomesModule.secondaryOutcomes","source_count":4,"title":"Secondary endpoints"},{"claim_count":10,"coverage":"discussed","id":"T6","registry_field":"conditionsModule","source_count":3,"title":"Population and setting"},{"claim_count":2,"coverage":"discussed","id":"T7","registry_field":"armsInterventionsModule.armGroups","source_count":2,"title":"The comparison"},{"claim_count":8,"coverage":"discussed","id":"T8","registry_field":"outcomesModule","source_count":4,"title":"Safety and tolerability"},{"claim_count":5,"coverage":"discussed","id":"T9","registry_field":"designModule","source_count":3,"title":"Design and conduct"},{"claim_count":14,"coverage":"discussed","id":"A1","source_count":4,"title":"Early response signals and the need to demonstrate outcome improvement"},{"claim_count":6,"coverage":"discussed","id":"A2","source_count":2,"title":"Dose sequencing and explanations for differentiation-syndrome differences"},{"claim_count":3,"coverage":"discussed","id":"A3","source_count":1,"title":"Younger-fit triplets and a less-intensive bridge to transplant"}],"counts":{"cited_sources":7,"claims_by_expression_type":{"comparison":5,"experience":8,"interpretation":3,"opinion":3,"question":2,"restatement":5,"uncertainty":4,"unspecified":4},"claims_by_kind":{"interpretation":2,"limitation":3,"source_observation":29},"clinician_statements":19,"evidence_units":18,"findings":4,"people_cited":7,"people_identity_verified":5,"people_total":7,"screened_sources":8,"verified_claims":34},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":10,"claims_by_group":{"comparisons":2,"experience":3,"questions":1,"restated":0,"views":4},"has_counterview":false,"limitations":3,"links":{"context":4,"support":12},"ma_question":true,"named_voices":4,"passages":11,"sources":4,"sources_by_kind":{"commentary":1,"media":3}},"title":"Frontline enthusiasm rests on early response signals, not established outcome improvement"},{"id":"F2","structure":{"claims":5,"claims_by_group":{"comparisons":1,"experience":1,"questions":2,"restated":0,"views":1},"has_counterview":false,"limitations":4,"links":{"context":3,"support":5},"ma_question":true,"named_voices":1,"passages":2,"sources":1,"sources_by_kind":{"media":1}},"title":"The intensive-treatment rationale depends on relapse risk and the earlier cohort's selection"},{"id":"F3","structure":{"claims":6,"claims_by_group":{"comparisons":1,"experience":2,"questions":1,"restated":0,"views":2},"has_counterview":false,"limitations":3,"links":{"context":3,"support":6},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"media":3}},"title":"Favorable tolerability reports leave differentiation-syndrome comparisons and scheduling effects unresolved"},{"id":"F4","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":3,"restated":0,"views":0},"has_counterview":false,"limitations":3,"links":{"context":3,"support":3},"ma_question":true,"named_voices":1,"passages":3,"sources":1,"sources_by_kind":{"media":1}},"title":"Triplet selection, dosing and a less-intensive bridge to transplant remain open questions"}],"medical_affairs_question":"What evidence would justify moving from encouraging response depth to confidence in improved frontline outcomes?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Frontline enthusiasm rests on early response signals, not established outcome improvement"},{"id":"section-2","level":2,"title":"The intensive-treatment rationale depends on relapse risk and the earlier cohort's selection"},{"id":"section-3","level":2,"title":"Favorable tolerability reports leave differentiation-syndrome comparisons and scheduling effects unresolved"},{"id":"section-4","level":2,"title":"Triplet selection, dosing and a less-intensive bridge to transplant remain open questions"},{"id":"section-5","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":1}],"id":"T1","label":"Primary endpoint: Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS)"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T2","label":"Primary endpoint: Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR)"},{"findings":[],"id":"T3","label":"Primary endpoint: Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS)"},{"findings":[{"id":"F3","shared_claims":1}],"id":"T4","label":"Primary endpoint: Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients"},{"findings":[{"id":"F1","shared_claims":4},{"id":"F3","shared_claims":6}],"id":"T5","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F4","shared_claims":3}],"id":"T6","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1}],"id":"T7","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2},{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":6}],"id":"T8","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":3}],"id":"T9","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-19T01:10:16.551444Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-19T01:27:29Z","record_hash":"609092ad4b4110cd5b5e56542f70a16ccb618ecc69ccfccf1fd2dc5f914aac1e","release_hash":"76bdeac3e5d20ffeb8265539f86f7e7218ffed00d5e3e7d200a3901eff0b4760","report_id":"erudio-nct07007312","run_id":"8997251d-7253-42dc-b780-0dc9bb6c3ce7","schema_version":"5.0","slug":"ko-men-017-07007312","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"KO-MEN-017 asks whether adding ziftomenib to intensive or nonintensive treatment improves outcomes in untreated NPM1-mutated or KMT2A-rearranged AML. Clinicians in the sources reviewed for this edition make the intensive-treatment rationale conditional on patient selection, while leaving triplet selection open. Their enthusiasm for frontline combinations accompanies scrutiny of differentiation-syndrome comparisons and treatment scheduling. Whether outcomes improve and how triplets should be dosed remain unresolved.","meta_description":"8 sources screened · 34 verified statements (19 from speakers with a confirmed clinical role) from 7 sources · 4 findings. Updated Oct 19, 2026.","person_names_policy":"role_only","sample_findings":[]},"publication":{"approved_at":"2026-10-19T01:27:29Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-10-19T03:09:55Z","summary":"Report description rewritten to say where clinicians' views stand, not only what they discuss"},{"affected_ids":[],"date":"2026-10-19T03:10:02Z","summary":"taxonomy mapping corrected"}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":8},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some clinician views in the sources used in this report are not yet captured as evidence in this edition; the next refresh takes them up.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","16 statements in the sources reviewed for this edition discuss other treatment settings or topics unrelated to this trial's question and are not included.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The discussion comes from the sources reviewed for this edition and cannot establish how common these views are among HCPs. Several posts report presentations rather than independent clinical assessments.","No protocol or results publication for the exact KOMET-017 trial was identified. The clinical observations discussed here must not be treated as randomized KOMET-017 findings.","The earlier response and safety accounts often omit denominators, follow-up duration or numerical rates. Zeidan's 40-patient response figures cannot be assigned to a specific frontline or relapsed/refractory cohort from the passage.","Speaker descriptions differ in regimen detail: Zeidan named azacitidine/venetoclax, whereas Zeidner's older/unfit KOMET-017 comparison named azacitidine without venetoclax. These descriptions do not establish a clinical disagreement.","The differentiation-syndrome comparisons concern different inhibitors, schedules and treatment settings. They do not establish a head-to-head safety advantage or a causal effect of starting treatment later."]},"sources":{"cited_sources":{"by_channel":{"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":4,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":7},"count":7,"evidence_window":{"end":"2026-10-14","start":"2025-02-11"},"retrieval_snapshot":"2026-10-18T19:18:57.369736Z","timeline":[{"count":1,"week":"2025-W07"},{"count":1,"week":"2025-W24"},{"count":3,"week":"2025-W50"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W42"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07007312:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07007312:context","quote_policy":"short_quote_link_out"},{"id":"openfda:b650f696-3391-4274-8b55-a5f5e9d04769:20251209","quote_policy":"short_quote_link_out"},{"id":"openfda:b118a40d-6b56-cee3-10f6-ded821a97018:20260520","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1933184132646899814:5bef8c44-9421-4fa4-8fbb-67ca35e1f4be","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998065126230851945:eef0852b-4aec-4dec-aebb-a2f2cee9cf51","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1998067825982771570:7aa0bbab-a421-4161-857d-42275b7aeb8a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2066086215141523898:21c00916-4d84-4cf5-bfc7-7a6b72c62030","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2088662396457951667:0b4233fb-45f0-47ef-9a91-3b897d600048","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:-AZ6_GmFKAA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:FmFpRIC20fA","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:kdu7KtcE-og","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":5,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":8},"count":8,"evidence_window":{"end":"2026-10-14","start":"2025-02-11"},"retrieval_snapshot":"2026-10-18T19:18:57.369736Z","timeline":[{"count":1,"week":"2025-W07"},{"count":1,"week":"2025-W24"},{"count":3,"week":"2025-W50"},{"count":1,"week":"2026-W24"},{"count":1,"week":"2026-W33"},{"count":1,"week":"2026-W42"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"brand_names":["Komzifti"],"label":"ziftomenib","slug":"ziftomenib"},{"brand_names":["Venclexta"],"label":"venetoclax","slug":"venetoclax"},{"brand_names":["Onureg","Vidaza"],"label":"azacitidine","slug":"azacitidine"},{"brand_names":["Cerubidine"],"label":"daunorubicin","slug":"daunorubicin"},{"brand_names":["Cytosar-U"],"label":"cytarabine","slug":"cytarabine"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Acute myeloid leukemia","slug":"acute-myeloid-leukemia"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"aliases":["Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia"],"brief_title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Acute Myeloid Leukemia (AML)"],"enrollment":{"count":1300,"type":"ESTIMATED"},"interventions":[{"name":"Ziftomenib","synonyms":["KO-539"],"type":"DRUG"},{"name":"Placebo","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Venetoclax","synonyms":["Venclexta","Venclyxto"],"type":"DRUG"},{"name":"Azacitidine (AZA)","synonyms":["Vidaza","Azadine"],"type":"DRUG"},{"name":"Daunorubicin","synonyms":["Cerubidine","daunomycin"],"type":"DRUG"},{"name":"Cytarabine (Ara-C)","synonyms":["cytosine arabinoside (ara-C)","Cytosar-U","Tarabine PFS"],"type":"DRUG"}],"nct_id":"NCT07007312","official_title":"Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination With Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients With Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2031-11","type":"ESTIMATED"},"primary_endpoints":[{"description":"OS","measure":"Nonintensive Therapy Study: (Primary Endpoint for all countries): Overall survival (OS)","timeFrame":"Defined as the time from randomization to date of death from any cause, assessed up to 36 months after last patient inclusion"},{"description":"CR rate per European Leukemia Network (ELN) 2022 criteria per Investigator assessment","measure":"Nonintensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR)","timeFrame":"Assessed up to 36 months after last patient inclusion"},{"description":"EFS","measure":"Intensive Therapy Study: (Primary Endpoint for all countries): Event-free survival (EFS)","timeFrame":"Defined as the time from randomization to treatment failure, hematologic relapse following CR, or death from any cause, whichever comes first, assessed up to 36 months after last patient inclusion"},{"description":"CR rate per ELN 2022 criteria per Investigator assessment with central BM MRD negativity","measure":"Intensive Therapy Study: (Dual Primary Endpoint for US & US reference countries only): Complete remission (CR) with bone marrow (BM) measurable residual disease (MRD) negativity in NPM1-m patients","timeFrame":"Assessed up to 36 months after last patient inclusion"}],"registry_last_updated":"2026-10-13","registry_url":"https://clinicaltrials.gov/study/NCT07007312","short_name":"KO-MEN-017","short_name_basis":"sponsor_study_id","sponsor":"Kura Oncology, Inc.","start_date":{"date":"2025-09-26","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"KO-MEN-017","type":"sponsor_study_id"},{"id":"2025-521314-25-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}